title: Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial.
abstract: The effectiveness of intermittent topical tacrolimus to prevent relapse in patients with stabilized facial seborrhoeic dermatitis has not been evaluated. The aim of this study was to determine whether proactive use of 0.1% tacrolimus ointment can keep adult facial seborrhoeic dermatitis in remission. A total of 75 patients who had stabilized facial seborrhoeic dermatitis after 2 weeks' (open-label induction) treatment with 0.1% tacrolimus were randomized in a double-blind fashion to treatment with 0.1% tacrolimus once a week, twice a week, or vehicle twice a week, for 10 weeks (maintenance). Significant improvement in erythema, scaling and pruritus compared with baseline was maintained during the maintenance phase in both tacrolimus groups, but not in the vehicle group. The mean recurrence rate according to global assessment was significantly higher in the tacrolimus once-weekly group than in the twice-weekly group. In conclusion, twice-weekly treatment with 0.1% tacrolimus ointment had superior effects in keeping facial seborrhoeic dermatitis in remission.
authors: Department of Dermatology, Pusan National University School of Medicine, Busan, Korea.
authors: Tae-Wook
authors: TW
authors: Kim
authors: Je-Ho
authors: JH
authors: Mun
authors: Seung-Wook
authors: SW
authors: Jwa
authors: Margaret
authors: M
authors: Song
authors: Hoon-Soo
authors: HS
authors: Kim
authors: Hyun-Chang
authors: HC
authors: Ko
authors: Moon-Bum
authors: MB
authors: Kim
authors: Ki-Hoon
authors: KH
authors: Song
authors: Sook-Kyung
authors: SK
authors: Lee
authors: Jong-Keun
authors: JK
authors: Seo
authors: Deborah
authors: D
authors: Lee
authors: Byung-Soo
authors: BS
authors: Kim
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D012628:Dermatitis, Seborrheic / Q000175:diagnosis / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005148:Facial Dermatoses / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D012074:Remission Induction; D056910:Republic of Korea; D055502:Secondary Prevention; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D009824:Ointments; D016559:Tacrolimus